Home/Pipeline/Proprietary Strain Portfolio

Proprietary Strain Portfolio

Targeted Symptom Management

R&DActive DevelopmentN/A

Key Facts

Indication
Targeted Symptom Management
Phase
R&D
Status
Active Development
Company

About InterCure

InterCure's mission is to improve patients' quality of life through the development and global distribution of high-quality, pharmaceutical-grade cannabis products. Its key achievement is establishing a leading, vertically integrated position in Israel's medical cannabis market through its GMP-certified subsidiary, Canndoc. The company's strategy focuses on leveraging its clinical data, regulatory expertise, and production standards to expand into international markets and build a robust evidence-based medical franchise.

View full company profile